{"id":161405,"date":"2026-09-07T18:04:09","date_gmt":"2026-09-07T18:04:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/161405\/"},"modified":"2026-09-07T18:04:09","modified_gmt":"2026-09-07T18:04:09","slug":"novo-is-down-nearly-2-as-a-40-4-childhood-win-meets-two-trial-cancellations","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/161405\/","title":{"rendered":"Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/9069726\/novo-is-down-nearly-2-as-a-404-childhood-win-meets-two-trial-cancellations?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GuruFocus&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GuruFocus<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk (<a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:NYSE%3ANVO;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NYSE:NVO&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"stocks_tp\" rel=\"nofollow noopener\">NYSE:NVO<\/a>), the diabetes and obesity-treatment powerhouse, <a href=\"https:\/\/www.reuters.com\/legal\/litigation\/novo-scraps-two-more-heart-drug-trials-further-dimming-growth-beyond-obesity-2026-09-07\/\" data-ylk=\"slk:traded;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;traded&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">traded<\/a> at $46.60 Monday, down nearly 2%, as two clinical signals pulled the investment case in opposite directions. Reuters reported that Novo stopped two ziltivekimab heart-failure trials, punching another hole in its diversification strategy. But semaglutide simultaneously opened the door to a younger obesity market.  <\/p>\n<p>        <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/0ef1b34b9225452ead5e56a45d31536ab0b22435abc1116e73a491c2089f99a8\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fuserupload.gurufocus.com%2F2097002240157065216.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> <a href=\"https:\/\/www.gurufocus.com\/term\/gf-value\/NVO?r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_is_down_nearly_2%25_as_a_40.4%25_childhood_win_meets_two_trial_cancellations&amp;utm_term=NVO\" data-ylk=\"slk:NVO%20GF%20Value%20chart;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NVO GF Value chart&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">NVO GF Value chart<\/a>           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The <a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916600\" data-ylk=\"slk:STEP%20Young;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;STEP Young&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">STEP Young<\/a> trial enrolled 165 children aged 6 to under 12. After 68 weeks, 40.4% of semaglutide patients dropped below the obesity threshold, compared with zero placebo recipients, assuming full adherence. Both groups received diet and exercise support, more than 85% entered with severe obesity, and Novo found no new concerns involving growth or puberty.  <\/p>\n<p>    <a href=\"https:\/\/www.gurufocus.com\/stock\/NVO\/summary?search=nvo&amp;r=9e8553cee17e7be6cdee2cf7b0a937b5&amp;r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_is_down_nearly_2%25_as_a_40.4%25_childhood_win_meets_two_trial_cancellations&amp;utm_term=NVO\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Novo is Down Nearly 2% as a 40.4% Childhood Win Meets Two Trial Cancellations  \u00b7 us.finance.gurufocus         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo generated DKK33.39 billion of adjusted second-quarter operating profit from DKK78.49 billion of <a href=\"https:\/\/www.novonordisk.com\/investors\/financial-results.html?utm_source=chatgpt.com\" data-ylk=\"slk:revenue;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;revenue&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">revenue<\/a>, producing a muscular 42.5% margin. That cash machine can fund plenty of failed experiments, but ziltivekimab shows that building a second growth engine will not be easy. At $46.60, the stock sits 55.98% below its $105.85 GF Value, revealing just how much pessimism is already baked into the price. The pediatric result expands semaglutide&#8217;s scientific reach; detailed data, regulatory clearance and long-term patient persistence must now prove that it can expand the commercial opportunity.  <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the diabetes and obesity-treatment powerhouse, traded at $46.60 Monday,&hellip;\n","protected":false},"author":2,"featured_media":161406,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[75686,57860,3845,272,3859],"class_list":["post-161405","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-46-60","tag-gurufocus","tag-novo","tag-novo-nordisk","tag-nvo"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117231082839080646","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=161405"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161405\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/161406"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=161405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=161405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=161405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}